Clinical Trial Update: A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function [Phase 1]

View source ↗

Summary

This Phase 1 study investigates belantamab mafodotin as monotherapy in adults with multiple myeloma across varying degrees of renal impairment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Belantamab Mafodotin (belantamab mafodotin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING